Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 4

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 4
---
 prospectus or any accompanying prospectus supplement, or in any other subsequently
filed document which also is or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

<div align='center'>PROSPECTUS SUMMARY</div>

This summary highlights certain
information about us, this offering and information appearing elsewhere in this prospectus and in the documents we incorporate by
reference in this prospectus. This summary is not complete and does not contain all of the information that you should consider
before investing in our securities. After you carefully read this summary, to fully understand our Company and this offering and its
consequences to you, you should read this entire prospectus and any related free writing prospectus authorized by us, including the
information referred to under the heading “Risk Factors” in this prospectus beginning on page 8, and any related
free writing prospectus, as well as the other documents that we incorporate by reference into this prospectus, including our
financial statements and the notes to those financial statements, which are incorporated herein by reference from our Annual Report on Form 10-K for the year ended September 30, 2024, filed on December 17, 2024. Please read “Where You Can
Find More Information” on page 23 of this prospectus.

In this prospectus, unless context requires otherwise,
references to “we,” “us,” “our,” or “the Company” refer to Applied DNA Sciences, Inc.,
a Delaware corporation and its consolidated subsidiaries. Our trademarks currently used in the United States include Applied DNA Sciences®,
SigNature® molecular tags, SigNature® T molecular tags, fiberTyping®, SigNify®, Beacon®, CertainT®, LineaDNA®,
Linea RNAP, Linea™ COVID-19 Diagnostic Assay Kit, safeCircle® COVID-19 testing and TR8 pharmacogenetic
testing. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement
or sponsorship of us by, any other companies. All trademarks, service marks and trade names included in this prospectus are the property
of the respective owners.

<div align='center'>1</div>

Applied DNA Sciences, Inc.

Introduction

We are a biotechnology company developing and
commercializing technologies to produce and detect deoxyribon